Patents are legal documents drawn up by inventors and lawyers and granted by various patent offices around the world, to protect the inventors' intellectual property. The short description accompanying each patent in this Patents section is therefore taken from the legal document as is, with minor corrections for Greek symbols and obvious spelling errors. The patents included in this section may be for material products (defensins or defensin-like peptides or nucleic acid sequences, synthetic or natural) or for novel methods of detecting, quantitating, synthesizing, or delivering antimicrobial peptides/nucleic acid sequences in general. The curators' criterion for inclusion in this section is broader for novel methods than for material products, in the hope that these methods may in future be similarly applied to defensins.

Patents in which the defensins or defensin-like material products and methods as above are not novel, such as biomarker sets containing unmodified defensin or defensin-like peptides or oligonucleotides, are excluded from this section. The exception to such exclusions is where the patent provides other novel defensin-related material products or methods in addition to those non-novel of the biomarker set itself. This exclusion is because the reasonable presence of defensin or defensin-like sequences or indeed any other sequences in patented biomarker sets is necessarily attributed to some prior discovery of disease state correlation with such sequences. The curators have observed therefore that the novel discovery in biomarker-related patents is often the method of biomarker array analysis and validation as well as its resultant implications for diagnostics and prognostics. The expert evaluation of such biomarker analysis and validation is well outside the scope of the Defensins Knowledgebase. The reader is respectfully referred to a biomarker database specific to the disease to perform his own assessment of the validity of the biomarker.

Methods not pertaining to the antimicrobial activity of defensins, but where defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences are suggested in some unambiguous detail to play a useful role in the method, with or without supporting experimental evidence, are included as well in this section. Patents in which natural defensins are up/downregulated in a clearly defined signal transduction pathway as a result of the unrelated patented novel compound or method are also included. And lastly, all patents showing experimental work done with defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences, where such peptides or nucleic acid sequences are not the experimental controls, are included without exception.

The data in this section have been extracted from the academic version of SciFinder Scholar 2007 and from public Google search - a wide range of defensin-related patents are included.


Results 71 - 80 of 333

<< Previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | Next >>

Last updated: 20th February 2008

Patent No.: US 6887846
Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone.
Applicant: Catania AP, Lipton JM (2005)
Alpha-MSH and other amino acid sequences derived from alpha-MSH were determined to have antimicrobial influences, including against two major and representative cutaneous and mucosal pathogens; Staphylococcus aureus and Candida albicans, Pharmaceutical compositions useful as antimicrobial agents, including for use in reducing the viability of microbes, reducing the germination of yeasts, killing microbes without reducing the killing of microbes by human neutrophils, for treating inflammation in which there is microbial infection without reducing microbial killing, and for increasing the accumulation of cAMP in microbes are disclosed. The antimicrobial agent is selected from the group consisting of one or more peptides including the amino acid sequence KPV, one or more peptides including the amino acid sequence MEHFRWG, or a biologically functional equivalent of any of the foregoing. The most effective of the peptides were those bearing the C-terminal amino acid sequence of alpha-MSH. i.e., alpha-MSH (1-13), (6-13), and (11-13).

Patent No.: US 6887470
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components.
Applicant: Bridon DP, Ezrin AM, Milner PG, Holmes DL, Thibaudeau K (2005)
A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.

Patent No.: US 6884776
Antimicrobial peptides derived from ubiquicidine.
Applicant: Nibbering PH, Hiemstra PS, Van Den Barselaar MT, Pauwels EKJ, Feitsma RIJ (2005)
The invention relates to the use of ubiquicidine or optionally modified peptide fragments derived therefrom for the preparation of a drug for the treatment, diagnostics or prophylaxis of infections in humans and animals. A peptide fragment derived from ubiquicidine comprises for instance a preferably continuous series of at least 3, preferably at least 7-13 amino acids from the amino acid sequence of ubiquicidine; KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVVPTFGKKKGPN ANS (SEQ ID NO: 1). Hybrid molecules comprise for instance a cationic peptide with an antimicrobial action and/or a peptide fragment of ubiquicidine and/or a derivative thereof and one or more effector molecules.

Patent No.: US 6875903
Treatment of Staphylococcus infections.
Applicant: Bramley AJ, Plaut KI, Kerr D (2005)
The present invention relates to an improved approach for the treatment of microbial infections in mammals. Specifically, the invention provides methods and reagents for expressing in mammalian cells, proteins having anti-microbial activity. The invention provides both genes, which have been modified to allow expression and preferably secretion of active protein in desired mammalian cells or tissues, and methods of introducing such modified genes into desired mammalian cells and/or tissues. Most specifically, genes encoding anti-staphylococcal proteins are delivered to mammalian cells and/or tissues by methods of gene delivery, including gene therapy and the production of transgenic animals, for the treatment of mastitis in ruminant animals.

Patent No.: US 6872705
Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.
Applicant: Lyons RT (2005)
Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.

Patent No.: US 6867293
Polynucleotide constructs having at least one transcriptional enhancer and encoding a modified rice EPSPS enzyme.
Applicant: Andrews CJ, Bachoo S, Hawkes TR, Pickerill AP, Warner SAJ (2005)
The invention is directed to polynucleotide constructs having at least one transcriptional enhancer operably liked to a rice EPSPS promoter and to a sequence encoding the rice EPSPS chloroplast transit peptide and rice EPSPS enzyme, the encoded enzyme having a modified region that confers herbicide resistance.

Patent No.: US 6864068
Antifungal proteins.
Applicant: Rees SB, De Samblanx GW, Broekaert WF (2005)
Antifungal proteins which are analogues of the Rs-AFP2 protein and contain particular mutations in their amino acid sequence. The mutated proteins possess enhanced salt-tolerant antifungal activity. The proteins are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.

Patent No.: US 6846478
Promoting whole body health.
Applicant: Doyle MJ, Hunter-Rinderle SJ, Singer RE Jr., Wimalasena RL (2005)
The present invention relates to promoting whole body health in humans and animals by using topical oral compositions comprising a safe and effective amount of chlorite ion in admixture with a pharmaceutically acceptable carrier, said compositions being effective in controlling bacterial-mediated diseases and conditions present in the oral cavity and inhibiting the spread into the bloodstream of oral pathogenic bacteria and associated bacterial toxins and resultant inflammatory cytokines and mediators. The present invention also encompasses methods of use of these compositions by topically applying to the oral cavity, a safe and effective amount of chlorite ion to promote and/or enhance whole body health in humans and other animals.

Patent No.: US 287571
Protein sequence of human epididymis-specific defensin EP2D and uses in evaluating and regulating male fertility.
Applicant: Chan HC, Zhou C, Ng CP, Chung YW (2005)
The invention relates to the discovery that an epididymis-specific beta-defensin EP2D and its rat counterpart Bin1b, plays an important role in regulating sperm motility and therefore male fertility. In vivo antisense expts. show that suppressed expression of Bin1b results in reduced binding of Bin1b to caput sperm and in considerable attenuation of sperm motility and progressive movement. Thus, beta-defensin is important for the acquisition of sperm motility and the initiation of sperm maturation. Provided are methods for evaluating male fertility based on the level of EP2D bound to sperm, kits for evaluating male fertility, and methods for enhancing or suppressing fertility in a male by regulating the level of EP2D and the binding between sperm and EP2D. The protein sequence of human beta-defensin EP2D is provided. Viral vectors carrying EP2D or antisense DNA/siRNA for EP2D are provided to regulate sperm maturation and motility.

Patent No.: US 272645
Retrocyclin peptides as antimicrobial agents with potent activity against bacteria and viruses.
Applicant: Lehrer RI, Waring AJ, Cole AM, Hong TB (2005)
The present invention provides retrocyclin peptides as antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical compn. comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, esp. one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.